ReviewDiscover oncology2025
Unveiling the oncogenic functions of lncRNA PSMG3-AS1: a review of its biological roles in cancer.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) have emerged as crucial regulators of various biological processes, including gene expression, cell differentiation, and response to external stimuli. Among them, PSMG3-AS1 has gained attention due to its involvement in the regulation of tumorigenesis across multiple cancers. This review provides an overview of the biogenesis, distribution, and functional roles of lncRNAs, with a particular focus on PSMG3-AS1 and its impact on cancer development. PSMG3-AS1 has been shown to play an oncogenic role in diverse malignancies such as breast cancer, cervical squamous cell carcinoma, endometrial cancer, gastric cancer, Glioma, hepatocellular carcinoma, lung cancer, oral squamous cell carcinoma, and prostate carcinoma, where its overexpression correlates with poor prognosis and enhanced tumor aggressiveness. Mechanistically, PSMG3-AS1 promotes cancer progression by interacting with multiple regulatory networks, including miRNA-mediated pathways and epigenetic modifications, which influence key cellular processes such as proliferation, migration, and invasion. By functioning as a molecular sponge for specific miRNAs, PSMG3-AS1 modulates the tumor-suppressive effects of these miRNAs, contributing to an oncogenic environment. Additionally, the ability of PSMG3-AS1 to regulate gene expression through DNA methylation further underscores its role in cancer progression. The accumulating evidence suggests that PSMG3-AS1 may serve as both a prognostic biomarker and a potential therapeutic target. However, further research is necessary to fully understand the molecular mechanisms by which PSMG3-AS1 influences cancer biology and to explore its clinical implications in cancer diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.